High-Affinity Androgen Receptor Inhibitor ODM-201: Advanced Solution for Prostate Cancer Therapy
Explore the groundbreaking research and development of ODM-201, a next-generation androgen receptor inhibitor demonstrating superior efficacy and a favorable safety profile for prostate cancer treatment. Discover how this advanced pharmaceutical intermediate is poised to revolutionize therapy for castration-resistant prostate cancer (CRPC). We are a trusted manufacturer and supplier in China.
Get a Quote & SampleRevolutionizing Prostate Cancer Treatment with ODM-201
ODM-201
As a premier supplier and manufacturer of advanced pharmaceutical intermediates in China, we offer ODM-201 (CAS: 1297538-32-9). This potent androgen receptor (AR) inhibitor exhibits exceptional binding affinity and effectively antagonizes mutant ARs that contribute to treatment resistance in castration-resistant prostate cancer (CRPC). Our commitment to quality ensures you receive high-purity ODM-201 for your critical research and development needs.
- Potent AR Antagonist: ODM-201 effectively blocks androgen receptor signaling, offering a novel approach to combating prostate cancer.
- Overcomes Resistance: It targets AR mutations that confer resistance to existing therapies, providing a solution for difficult-to-treat cases.
- Favorable Safety Profile: With negligible brain penetrance, ODM-201 is associated with a lower risk of central nervous system side effects.
- Advanced Pharmaceutical Intermediate: Procure high-quality ODM-201 from a reliable manufacturer and supplier in China for your formulation needs.
Key Advantages of ODM-201
Superior Efficacy in CRPC
ODM-201 demonstrates significantly higher antitumor activity compared to existing second-generation antiandrogens in preclinical models, making it a superior choice for treating advanced prostate cancer.
Broad Spectrum Activity
Unlike other antiandrogens, ODM-201 functions as a full antagonist against all tested AR mutations, including F876L, W741L, and T877A, which are known drivers of resistance.
Enhanced Patient Safety
The minimal brain penetrance of ODM-201 significantly reduces the risk of neurological adverse events, such as seizures, often associated with other AR inhibitors, ensuring better patient tolerance.
Applications and Research
Prostate Cancer Therapy
ODM-201 is a promising agent for the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly for patients who have developed resistance to standard therapies. Explore how to buy ODM-201 from our China manufacturing facility.
Oncology Drug Development
As a cutting-edge pharmaceutical intermediate, ODM-201 is invaluable for ongoing research in novel oncology drug development. We are a leading supplier offering competitive pricing for bulk purchases.
AR Signaling Research
Investigate the complex mechanisms of androgen receptor signaling and resistance pathways with ODM-201. Our company provides detailed product specifications and technical support to researchers worldwide.
Pharmaceutical Intermediate Sourcing
For pharmaceutical companies seeking a reliable supplier of high-purity ODM-201 in China, we offer consistent quality and efficient global distribution. Request a quote for your procurement needs.